Partnership for Part D Access
  • Home
  • About Us
    • Who We Are
    • Patient Communities
    • Our Leadership
  • The Issue
    • Six Protected Classes
    • History
  • Resources
  • Newsroom
  • Stakeholder Voices
  • Contact Us
  • Home
  • About Us
    • Who We Are
    • Patient Communities
    • Our Leadership
  • The Issue
    • Six Protected Classes
    • History
  • Resources
  • Newsroom
  • Stakeholder Voices
  • Contact Us

Newsroom​ 

National Law Review: CMS Proposes Changes to Lower Drug Prices

12/6/2018

0 Comments

 
Picture
​In a recent article for National Law Review that examines CMS’ new rule on Part D,the authors cite the Partnership’s recent Avalere report that casts doubt on the proposed rule’s beneficial effects . The piece highlights key data points in Partnership’s report showing that the current system controls costs in a variety of ways, including copayments for expensive brand drugs and promoting generic utilization. “As such, changes to the current system motivated solely by overall cost could be detrimental for certain high risk patients who are receiving treatments including cancer, HIV, and kidney transplants that require expensive drugs with high copayments and no generic options,” the authors point out. “There is further concern that reducing the protections of certain medications will ultimately lead to their exclusion from Part D plan formularies.”

0 Comments

    Author

    Write something about yourself. No need to be fancy, just an overview.

    Archives

    September 2022
    November 2021
    March 2021
    February 2021
    January 2021
    November 2020
    January 2020
    July 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    April 2018
    March 2018
    September 2017
    May 2017
    April 2017
    November 2016
    July 2016

    Categories

    All

    RSS Feed

Learn more

About Us
Patient Communities
​Issues
​Background

What's New?

​Newsroom
Resources
​

Contact

Contact Us
© COPYRIGHT 2018. ALL RIGHTS RESERVED.